---
schema_version: "secwatch.filing_event.v1"
accession: "0001743881-26-000008"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:50:55.205782+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BridgeBio reports Q4 net product revenue $146M; three positive Phase 3 trials

## Summary
- Q4 net loss $192.9M ($1.00/share); FY net loss $724.9M ($3.78/share).
- Attruby (ATTR-CM) net product revenue $146.0M in Q4; 7,804 patient prescriptions as of Feb 20.
- Phase 3 FORTIFY (LGMD2I/R9) met endpoints; 2.6-point NSAD improvement vs placebo at 12 months.
- Phase 3 PROPEL 3 (infigratinib, achondroplasia) met primary endpoint; mean AHV +2.10 cm/year vs placebo.
- Cash $587.5M at Dec 31; completed $632.5M convertible notes Jan 2026.

## SEC filing metadata
- accession: 0001743881-26-000008
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000174388126000008/0001743881-26-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000174388126000008/bbio-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001743881-26-000008
- JSON: https://secwatch.observer/filing/0001743881-26-000008.json
- Plain text: https://secwatch.observer/filing/0001743881-26-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.